biostudies-literatureBatteson Rthe healthcare business of Merck KGaA, Darmstadt, GermanyNCI NIH HHS191-201https://www.ebi.ac.uk/biostudies/studies/S-EPMC10963552biostudies-literatureUnknown19(2)<h4>Background</h4>Patients with non-small cell lung cancer harbouring mesenchymal-epithelial transition exon 14 (METex14) skipping typically demonstrate poorer prognosis than overall non-small cell lung cancer. Until recently, no targeted treatments were available for patients with non-small cell lung cancer harbouring METex14 skipping in the UK, with limited treatments available.<h4>Objective</h4>This study estimates the long-term survival and quality-adjusted life-year benefit of MET inhibitor tepotinib versus current standard of care from a UK perspective.<h4>Methods</h4>A partitioned-survival model assessed the survival and quality-adjusted life-year benefits of tepotinib versus immunotherapy ± chemotherapy and chemotherapy for untreated and previously treated patients, respectively, Targeted oncologyModelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK.PMC10963552P30 CA008748McLean THatswell AJVioix HBatteson RBaijal SHook EAlexopoulos STPaik PKWheat HfalseModelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK.<h4>Background</h4>Patients with non-small cell lung cancer harbouring mesenchymal-epithelial transition exon 14 (METex14) skipping typically demonstrate poorer prognosis than overall non-small cell lung cancer. Until recently, no targeted treatments were available for patients with non-small cell lung cancer harbouring METex14 skipping in the UK, with limited treatments available.<h4>Objective</h4>This study estimates the long-term survival and quality-adjusted life-year benefit of MET inhibitor tepotinib versus current standard of care from a UK perspective.<h4>Methods</h4>A partitioned-survival model assessed the survival and quality-adjusted life-year benefits of tepotinib versus immunotherapy ± chemotherapy and chemotherapy for untreated and previously treated patients, respectively, 2024-01-01T00:00:00Z2024 Mar2026-06-01T05:36:47.218Z2026-04-08T09:38:37.327ZS-EPMC109635523849215710.1007/s11523-024-01038-z